Jane Street
INTS icon

Jane Street’s Intensity Therapeutics INTS Stock Holding History

Jane Street’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,510
Closed -$25.7K – 12246
2025
Q4 		$25.7K Buy
+2,510
New +$25.5K ﹤0.01% 10676
2025
Q3 		– Sell
-1,796
Closed -$13.8K – 11250
2025
Q2 		$13.8K Buy
+1,796
New +$36.9K ﹤0.01% 9389

Other funds holding INTS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jane Street's INTS Position: Q1 2026 in Review

Jane Street sold out of Intensity Therapeutics (INTS) in Q1 2026, closing a stake of 2,510 shares — an estimated $25.7K sold.

Jane Street first reported a position in INTS in Q2 2025 and held it in 2 quarters. The position peaked at $25.7K in Q4 2025. 13 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

  • Jane Street reported no remaining Intensity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 2,510 Intensity Therapeutics shares in Q1 2026, an estimated $25.7K.
  • Jane Street first reported a position in Intensity Therapeutics in Q2 2025 and held it in 2 quarters.
  • Jane Street's Intensity Therapeutics position peaked at $25.7K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.